Change search
ReferencesLink to record
Permanent link

Direct link
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
Department of Oncology, Karolinska Institute and University Hospital, Stockholm, Sweden.
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology.
Department of Oncology, Sundsvall Hospital, Sweden.
Department of Oncology, Gävle Hopsital, Sweden.
Show others and affiliations
2011 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 50, no 1, 35-41 p.Article in journal (Refereed) Published
Abstract [en]

The aim of the study was to evaluate the feasibility of tailored and dose-dense epirubicin and cyclophosphamide followed by docetaxel as adjuvant breast cancer therapy. Material and methods. Patients with node-positive breast cancer received either four cycles of biweekly and tailored EC (epirubicin 38-60-75-90-105-120 mg/m(2), cyclophosphamide 450-600-900-1200 mg/m(2)) followed by four cycles of docetaxel (60-75-85-100 mg/m(2)) (arm A) or the same regimen with fixed doses (E(90)C(600) + 4 → T(75) + 4) (arm B) or docetaxel, doxorubicin and cyclophosphamide (T(75)A(50)C(500)) every three weeks for six cycles (arm C). All patients received G-CSF support and prophylactic ciprofloxacin. Results. One-hundred and twenty-four patients were randomised in the study. In the A, B and C arm, 17% 19% and 3% of the patients had one or more cycles delayed due to side-effects whereas 24%, 5% and 15% experienced a grade 3 infection or febrile neutropenia. After the introduction of an extra week between the EC and T parts in the A and B arms, grade 3 hand-foot-skin reactions were reduced from 5 to 0.2%. Twenty-nine percent (A and B) and 20% (C) of the patients were hospitalised due to side-effects. Discussion. Dose-dense and tailored EC/T can be given with manageable toxicity and is after adjustment presently studied in the phase III Panther trial.

Place, publisher, year, edition, pages
2011. Vol. 50, no 1, 35-41 p.
National Category
Cancer and Oncology
Research subject
URN: urn:nbn:se:umu:diva-39285DOI: 10.3109/0284186X.2010.535847PubMedID: 21174610OAI: diva2:390013
Available from: 2011-01-20 Created: 2011-01-20 Last updated: 2011-09-27Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Bengtsson, Nils-Olof
By organisation
In the same journal
Acta Oncologica
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 82 hits
ReferencesLink to record
Permanent link

Direct link